N-acetylcysteine,
does it really help with Reduced hair-pulling urges, behavior, and severity in adults with trichotillomania?
research showsIn a 12-week double-blind randomized trial of 50 adults with trichotillomania, NAC 1,200 to 2,400 mg/day reduced hair-pulling severity and produced response rates of 56% versus 16% with placebo. Adult efficacy, however, rests essentially on this single trial, while a 39-participant pediatric trial found no significant benefit. The 2021 Cochrane review judged evidence insufficient to confirm or refute medication efficacy and identified the adult NAC signal as one small trial, supporting D.
ads claimMarketing can portray a single adult study as established treatment for every age or as an approved indication comparable to mucolytic use. Psychiatric use for trichotillomania is off-label and does not replace behavioral treatment, particularly habit-reversal training.
Useful facts when choosing a product
- Common Korean medicinal indications for NAC are mucolytic; treatment of trichotillomania is an off-label psychiatric use.
- The pivotal adult study used 1,200 to 2,400 mg/day for 12 weeks, and formulations, excipients, and directions vary by product.
- Nausea, diarrhea, abdominal discomfort, and unpleasant odor are common limitations, while rash or hypersensitivity is uncommon. Asthma, gastrointestinal disease, and concomitant medicines warrant advice.
What the research actually shows
The Grant trial randomized 50 adults to NAC or placebo for 12 weeks, titrating NAC from 1,200 to 2,400 mg/day. The MGH Hair Pulling Scale and Psychiatric Institute Trichotillomania Scale improved, with clinical response in 56% versus 16%. The Bloch trial administered 12-week add-on NAC to 39 participants aged 8 to 17 and found no significant benefit on any outcome. Cochrane 2021 reported an adult response risk ratio of 3.5 but emphasized that this came from one 50-person trial and that medication evidence remained insufficient overall.
Why this is classified as D (38)
The positive 56% versus 16% response in one 50-adult trial lacks independent adult replication, and a 39-person pediatric trial was negative. Cochrane also judged the evidence insufficient and single-trial based, yielding D with 38 points.
Counterpoint. It may be an adjunctive off-label option for an adult with persistent symptoms after behavioral care and informed clinical review, but self-treatment does not have evidence to replace established therapy.
Rejudgment record. New verdict — The 56% versus 16% response in a 50-adult, 12-week trial was accepted, but absent independent adult replication, a negative 39-person pediatric trial, and Cochrane's single-trial evidence limitation require D under rule ②
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced hair-pulling urges and behavior in adults | D | One 50-adult trial was positive, but no independent adult replication exists. |
| Reduced symptom severity in adults | D | Two severity scales improved, but the evidence comes from one trial. |
| Reduced trichotillomania symptoms in children and adolescents | D | A 39-participant randomized trial found no significant benefit over placebo. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Grant JE et al. 2009 | Twelve-week randomized double-blind placebo-controlled trial | 50 | Academic research with disclosed product-supply context | MGH-HPS, PITS, and clinical response | Symptom scales improved significantly and response was 56% with NAC versus 16% with placebo. | Key direct adult efficacy evidence; one small trial |
| Bloch MH et al. 2013 | Twelve-week randomized double-blind placebo-controlled add-on trial | 39 | Trichotillomania Learning Center and academic support | Hair-pulling severity and clinical response | No efficacy outcome differed significantly between NAC and placebo. | Nonreplication evidence with age indirectness |
| Hoffman J et al. 2021 Cochrane review | Systematic review and meta-analysis of pharmacotherapy | 50 | Cochrane and academic research | Treatment response, symptom severity, and adverse events | An adult NAC signal existed, but evidence was insufficient to confirm or refute efficacy of any medication. | Key synthesis |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] N-acetylcysteine x reduced adult trichotillomania symptoms — Evidence Grade D·38. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/n-acetylcysteine-adult-trichotillomania-hair-pulling/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.